Hubei Xingfa Chemicals Group Reports Decline in Quarterly Earnings and Modest Growth in Annual Revenue
Hubei Xingfa Chemicals Group Co. Ltd (SH 600141), a Shanghai‑listed producer of phosphoric chemicals, released its financial results for the quarter ended 31 December 2025 on 3 April 2026. The company’s earnings‑per‑share (EPS) fell to CNY 0.16 from CNY 0.26 a year earlier, reflecting a 13.0 % drop in quarterly revenue to CNY 5.52 billion. In contrast, year‑to‑date revenue for the same period rose by 3.2 % to CNY 29.25 billion, a modest improvement over the prior year’s CNY 28.35 billion.
Quarterly Highlights
| Metric | 2025 Q4 | 2024 Q4 | % Change |
|---|---|---|---|
| EPS (CNY) | 0.16 | 0.26 | –38.5 % |
| Revenue (CNY bn) | 5.52 | 6.35 | –13.0 % |
The sharp contraction in EPS aligns with the decline in quarterly sales, suggesting tighter margins or higher cost pressures within the phosphoric chemicals segment. The company’s 52‑week low (CNY 19.24) and high (CNY 45.49) illustrate the volatility that can accompany commodity‑driven production.
Annual Performance
For the full year 2025, the company recorded CNY 1.35 EPS, down from CNY 1.45 in 2024. Revenue for the year was reported at CNY 29.25 billion, slightly above analysts’ consensus of CNY 29.98 billion but below the 2024 figure of CNY 28.35 billion. The 2025 profit decline mirrors the quarterly trend, while the revenue uptick indicates some resilience in the company’s export markets—particularly the United States, Japan, Brazil, and Vietnam.
Market Context
With a market capitalization of approximately CNY 5.31 billion, Hubei Xingfa operates in a niche segment of the broader chemicals industry, focusing on yellow phosphorus, glyphosate, phosphorus trichloride, and phosphoric acid. Its price‑earnings ratio of 23.33 positions it above many peers, reflecting expectations of future growth or higher risk.
The company’s latest EPS and revenue figures suggest that while the business continues to generate significant sales, profitability is under pressure. Investors may view the modest revenue increase as a positive sign, but the declining EPS could temper enthusiasm until margin‑enhancing initiatives or cost‑control measures take effect.
Outlook
Analysts are monitoring the company’s ability to navigate commodity price swings and supply‑chain disruptions. The firm’s commitment to maintaining a diversified customer base across several key international markets may help cushion against regional downturns. However, the recent earnings drop signals the need for continued scrutiny of the company’s cost structure and operational efficiency as it seeks to sustain profitability in a competitive chemicals landscape.
